Vancouver, Wash.-based biotech company AbSci raised an undisclosed amount of funding from pharmaceutical giant Merck. Founded in 2011, AbSci’s “Protein Printing” technology is used to discover and manufacture complex biological molecules such as antibodies and insulin. The investment comes from Merck’s Global Health Innovation Fund, which has $500 million under management. A SEC filing posted Feb. 26 notes a $70 million cash infusion for the company. AbSci declined to comment on the filing or provide financial details of the deal.